Quotes: US MENA   Enter Symbol: NewsLetter: Search: advanced

Genetically engineered virus kills cancer: study  Join our daily free Newsletter

MENAFN - AFP - 10/02/2013

No. of Ratings : 0
Add to Mixx!


 


(MENAFN - AFP) A genetically-engineered virus tested in 30 terminally-ill liver cancer patients significantly prolonged their lives, killing tumours and inhibiting the growth of new ones, scientists reported on Sunday.Sixteen patients given a high dose of the therapy survived for 14.1 months on average, compared to 6.7 months for the 14 who got the low dose."For the first time in medical history we have shown that a genetically-engineered virus can improve survival of cancer patients," study co-author David Kirn told AFP.The four-week trial with the vaccine Pexa-Vec or JX-594, reported in the journal Nature Medicine, may hold promise for the treatment of advanced solid tumours."Despite advances in cancer treatment over the past 30 years with chemotherapy and biologics, the majority of solid tumours remain incurable once they are metastatic (have spread to other organs)," the authors wrote.There was a need for the development of "more potent active immunotherapies", they noted.Pexa-Vec "is designed to multiply in and subsequently destroy cancer cells, while at the same time making the patients' own immune defence system attack cancer cells also," said Kirn from California-based biotherapy company Jennerex."The results demonstrated that Pexa-Vec treatment at both doses resulted in a reduction of tumour size and decreased blood flow to tumours," said a Jennerex statement."The data further demonstrates that Pexa-Vec treatment induced an immune response against the tumour."Pexa-Vec has been engineered from the vaccinia virus, which has been used as a vaccine for decades, including in the eradication of smallpox.The trial showed Pexa-Vec to be well tolerated both at high and low doses, with flu-like symptoms lasting a day or two in all patients and severe nausea and vomiting in one.The authors said a larger trial has to confirm the results. A follow-up phase with about 120 patients is already underway.Pexa-Vec is also being tested in other types of cancer tumours.

 






  MENA News Headlines


 






Google

 
 

Middle East North Africa - Financial Network

MENAFN News Market Data Countries Tools Section  
 

Middle East North Africa - Financial Network
Arabic MENAFN

Main News
News By Industry
News By Country
Marketwatch News
UPI News
Comtex News

IPO News
Islamic Finance News
Private Equity News

How-To Guides
Technology Section

Travel Section

Search News

Market Indices
Quotes & Charts

Global Indices
Arab Indices

US Markets Details

Commodoties

Oil & Energy

Currencies Cross Rates
Currencies Updates
Currency Converter

USA Stocks
Arab Stocks
 

Algeria 
Bahrain 
Egypt 
Iraq
Jordan 
Kuwait 
Lebanon
Morocco 
Oman 
Palestine
Qatar 
Saudi Arabia 
Syria
Tunisia 
UAE 
Yemen

Weather
Investment Game
Economic Calendar
Financial Glossary

My MENAFN
Portfolio Tracker

Voting

Financial Calculators

RSS Feeds [XML]

Corporate Monitor

Events

Real Estate
Submit Your Property

Arab Research
Buy a Research

Press Releases
Submit your PR

Join Newsletters


 
© 2000 menafn.com All Rights Reserved.  Terms of Service | Privacy Policy | Contact Us | Advertise | About MENAFN | Career Opportunities | Feedback | Help